vs
RLI CORP（RLI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是RLI CORP的1.3倍（$622.0M vs $465.7M），Royalty Pharma plc净利率更高（34.4% vs 19.6%，领先14.9%），RLI CORP同比增速更快（6.1% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.3%）
RLI Corp是一家总部位于美国伊利诺伊州皮奥里亚的专业保险公司，主营财产保险与意外伤害保险业务，深耕保险领域多年，凭借成熟的风险管控体系与定制化产品矩阵，为不同类型的客户提供全面可靠的风险保障服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
RLI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$465.7M
营收增速更快
RLI
高出1.3%
4.8%
净利率更高
RPRX
高出14.9%
19.6%
两年增速更快
RPRX
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $465.7M | $622.0M |
| 净利润 | $91.2M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 24.4% | 62.4% |
| 净利率 | 19.6% | 34.4% |
| 营收同比 | 6.1% | 4.8% |
| 净利润同比 | 123.1% | 2.9% |
| 每股收益（稀释后） | $1.00 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RLIRPRX
| Q4 25 | $465.7M | $622.0M | ||
| Q3 25 | $509.3M | $609.3M | ||
| Q2 25 | $499.8M | $578.7M | ||
| Q1 25 | $407.7M | $568.2M | ||
| Q4 24 | $439.1M | $593.6M | ||
| Q3 24 | $470.0M | $564.7M | ||
| Q2 24 | $416.4M | $537.3M | ||
| Q1 24 | $444.8M | $568.0M |
净利润RLIRPRX
| Q4 25 | $91.2M | $214.2M | ||
| Q3 25 | $124.6M | $288.2M | ||
| Q2 25 | $124.3M | $30.2M | ||
| Q1 25 | $63.2M | $238.3M | ||
| Q4 24 | $40.9M | $208.2M | ||
| Q3 24 | $95.0M | $544.0M | ||
| Q2 24 | $82.0M | $102.0M | ||
| Q1 24 | $127.9M | $4.8M |
营业利润率RLIRPRX
| Q4 25 | 24.4% | 62.4% | ||
| Q3 25 | 30.9% | 70.1% | ||
| Q2 25 | 31.3% | 36.3% | ||
| Q1 25 | 19.3% | 94.0% | ||
| Q4 24 | 10.8% | 60.9% | ||
| Q3 24 | 24.9% | — | ||
| Q2 24 | 24.8% | 50.2% | ||
| Q1 24 | 36.0% | -13.0% |
净利率RLIRPRX
| Q4 25 | 19.6% | 34.4% | ||
| Q3 25 | 24.5% | 47.3% | ||
| Q2 25 | 24.9% | 5.2% | ||
| Q1 25 | 15.5% | 41.9% | ||
| Q4 24 | 9.3% | 35.1% | ||
| Q3 24 | 20.2% | 96.3% | ||
| Q2 24 | 19.7% | 19.0% | ||
| Q1 24 | 28.8% | 0.8% |
每股收益（稀释后）RLIRPRX
| Q4 25 | $1.00 | $0.49 | ||
| Q3 25 | $1.35 | $0.67 | ||
| Q2 25 | $1.34 | $0.07 | ||
| Q1 25 | $0.68 | $0.55 | ||
| Q4 24 | $-2.87 | $0.46 | ||
| Q3 24 | $2.06 | $1.21 | ||
| Q2 24 | $1.78 | $0.23 | ||
| Q1 24 | $2.77 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.8B | $9.7B |
| 总资产 | $6.2B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资RLIRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务RLIRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $100.0M | $8.9B | ||
| Q2 25 | $100.0M | $8.0B | ||
| Q1 25 | $100.0M | $7.6B | ||
| Q4 24 | $100.0M | $7.6B | ||
| Q3 24 | $100.0M | $7.6B | ||
| Q2 24 | $100.0M | $7.6B | ||
| Q1 24 | $100.0M | $6.1B |
股东权益RLIRPRX
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.9B | $9.6B | ||
| Q2 25 | $1.7B | $9.5B | ||
| Q1 25 | $1.6B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.7B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B | ||
| Q1 24 | $1.5B | $9.9B |
总资产RLIRPRX
| Q4 25 | $6.2B | $19.6B | ||
| Q3 25 | $6.2B | $19.3B | ||
| Q2 25 | $6.0B | $18.3B | ||
| Q1 25 | $5.7B | $17.6B | ||
| Q4 24 | $5.6B | $18.2B | ||
| Q3 24 | $5.8B | $18.0B | ||
| Q2 24 | $5.5B | $17.7B | ||
| Q1 24 | $5.3B | $16.1B |
负债/权益比RLIRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.05× | 0.93× | ||
| Q2 25 | 0.06× | 0.84× | ||
| Q1 25 | 0.06× | 0.78× | ||
| Q4 24 | 0.07× | 0.74× | ||
| Q3 24 | 0.06× | 0.74× | ||
| Q2 24 | 0.06× | 0.78× | ||
| Q1 24 | 0.07× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $156.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $155.0M | — |
| 自由现金流率自由现金流/营收 | 33.3% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | 1.72× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $608.7M | — |
8季度趋势，按日历期对齐
经营现金流RLIRPRX
| Q4 25 | $156.8M | $827.1M | ||
| Q3 25 | $179.2M | $702.6M | ||
| Q2 25 | $174.7M | $364.0M | ||
| Q1 25 | $103.5M | $596.1M | ||
| Q4 24 | $128.1M | $742.5M | ||
| Q3 24 | $219.4M | $703.6M | ||
| Q2 24 | $141.8M | $658.2M | ||
| Q1 24 | $70.9M | $664.6M |
自由现金流RLIRPRX
| Q4 25 | $155.0M | — | ||
| Q3 25 | $177.8M | — | ||
| Q2 25 | $173.4M | — | ||
| Q1 25 | $102.5M | — | ||
| Q4 24 | $127.6M | — | ||
| Q3 24 | $219.0M | — | ||
| Q2 24 | $139.1M | — | ||
| Q1 24 | $69.9M | — |
自由现金流率RLIRPRX
| Q4 25 | 33.3% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 34.7% | — | ||
| Q1 25 | 25.1% | — | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 46.6% | — | ||
| Q2 24 | 33.4% | — | ||
| Q1 24 | 15.7% | — |
资本支出强度RLIRPRX
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.2% | — |
现金转化率RLIRPRX
| Q4 25 | 1.72× | 3.86× | ||
| Q3 25 | 1.44× | 2.44× | ||
| Q2 25 | 1.41× | 12.06× | ||
| Q1 25 | 1.64× | 2.50× | ||
| Q4 24 | 3.13× | 3.57× | ||
| Q3 24 | 2.31× | 1.29× | ||
| Q2 24 | 1.73× | 6.45× | ||
| Q1 24 | 0.55× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RLI
| Casualty Segment | $246.8M | 53% |
| Property Insurance Segment | $122.5M | 26% |
| Other | $59.3M | 13% |
| Surety Insurance Segment | $37.1M | 8% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
